Biomea Fusion(BMEA) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

BMEA Biomea Fusion

Watchlist

2.540
-0.120-4.51%

Close Mar 14 16:00 ET

2.540
0.0000.00%

Post 19:42 ET

92.05MMarket Cap-0.63P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Biomea Fusion, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswireMar 3 08:00 ET
Express News | Biomea Fusion Inc - Franco Valle Resigns as CFO of Biomea Fusion
ReutersFeb 28 16:06 ET
Express News | Biomea Fusion To Feature Presentations At 18th International Conference on Advanced Technologies & Treatments for Diabetes Mar. 18-20
BenzingaFeb 27 08:04 ET
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
GlobeNewswireFeb 27 08:00 ET
Biomea Fusion Price Target Cut to $16.00/Share From $128.00 by D. Boral Capital
Dow JonesJan 13 13:44 ET · Ratings
D. Boral Capital Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $16
Moomoo NewsJan 13 10:33 ET · Ratings

Comments

Kraks

Feb 26 03:34

No bottom?

$Biomea Fusion (BMEA.US)$ is on a free fall, no bottom in view...

我要向钱看

Jan 13 22:07

UPDATES

$Biomea Fusion (BMEA.US)$ Biomea Fusion (NASDAQ: BMEA) announced its strategic transformation into a diabetes and obesity medicines company, focusing on icovamenib development for metabolic disorders. The company will conclude its oncology studies and explore partnerships for these assets.
Key clinical trial results for icovamenib showed:
1.5% mean reduction in HbA1c in severe insulin deficient patients vs placebo
1.0% HbA1c reduction in patients on GLP-1-based therapies
100% response ...

Jaguar8

Jan 13 22:05

NEWS

$Biomea Fusion (BMEA.US)$
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Monday, 13th January at 9:00 am
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones
of the metabolic franchise
Biomea preparing icovamenib for late-stage clinical development
2025 corporate update to be presented at the 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company...

我要向钱看

Jan 10 21:13

🤔🤔🤔

$Biomea Fusion (BMEA.US)$ Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital

我要向钱看

Jan 7 22:21

NEW PRECLINICAL DATA

$Biomea Fusion (BMEA.US)$ New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared to semaglutide alone
Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose
Ex vivo human islet experiments pr...

Trending Stocks

Symbol Mini Chart % Chg

Unlock the Full List